The big asset swap between GlaxoSmithKline and Novartis may have given each just what it wanted, but the deal continues to play out poorly for workers, with GSK planning to close its Pittsburgh office where it has about 275 employees working for its consumer health unit.
Fitch Ratings is raising the flag on pharma M&A. The credit ratings agency says the current spate of dealmaking is putting some pressure on European Big Pharma players.
GlaxoSmithKline's controversial overhaul of sales-rep compensation is due for some tweaks. After replacing its North American president earlier this year, the company has decided to revisit its so-called Patient First sales model, which pegs incentive pay to broad sales and performance goals rather than individual quotas.
In the wake of its multibillion-dollar asset swap with Novartis, GlaxoSmithKline is doubling down on its vaccines focus. And it'll be doing that in Maryland, where it's establishing a new global R&D center.
The head of Cipla's India operations has resigned from his post just more than a year after joining from GlaxoSmithKline in January last year, the company said in an email to FiercePharmaAsia.
GlaxoSmithKline is setting up a global vaccines hub in Rockville, MD, in the wake of its big asset swap with Novartis. And the move will force hundreds of staffers in Cambridge, MA, and Philadelphia to either look for a relocation package or exit the company.
Though GlaxoSmithKline is still waiting on late-stage results from its shingles vaccine, HZ/su, Cowen & Co. analysts say the GSK shot may just be better than Merck's Zostavax.
While GlaxoSmithKline is still awaiting late-stage results for its shingles vaccine, HZ/su, Cowen & Co. analysts believe the vaccine may just be better than Merck's Zostavax.
Two Ebola vaccines, one developed by the NIH and GlaxoSmithKline and the other by Merck and NewLink, have sailed through Liberian trials and, based on the results, may now advance to Phase III trials.
GlaxoSmithKline and Johnson & Johnson have settled a short-lived legal spat over GSK's allergy drug marketing claims--meaning that now, the only battle left will be the one for market share.